Cognitive impairment related diseases
Conditions
Interventions
Alzheimer disease:Nil
MCI:Nil
Frontotemporal lobe dementia:Nil
Louis body dementia:Nil
Parkinson's disease / dementia:Nil
vascular cognitive impairment:Nil
normal Cognitive Control Group:Nil
Sponsors
First affiliated Hospital of China University of Science and Technology, Anhui Provincial Hospital
Eligibility
Sex/Gender
All
Age
40 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. The Alzheimer's disease was enrolled in the NIA-AA diagnostic criteria for 2011: the subject was in accordance with the criteria for the diagnosis of dementia; the onset of the onset of the disease gradually occurred in the months to several years; the patient's subjective report or the patient's observations made clear medical history of the cognitive impairment; and in the medical history and the body, The initial and most prominent cognitive domain impairment is often a memory disorder, and there should also be a cognitive domain that is damaged; a marker for brain-a-brain deposition: CSF A-42 reduction and PET A-imaging. Biomarkers of neuronal damage: the rise of the tau protein in the cerebrospinal fluid, the decrease of the glucose metabolism in the parietal lobe and the structural MRI, and the medial or lateral atrophy, and the medial cortical atrophy of the parietal lobe. The consent of all subjects and/ or guardians to the study was informed and informed consent was signed; 2. Mild cognitive impairment was enrolled in the NIA-AA diagnostic criteria for 2011: the concern about the change in cognition, and the concerns that the changes found in the previous level were likely to be derived from the patient's own, It may also be a practitioner or experienced doctor; the damage to one or more of the cognitive areas, including the memory, the execution function, the attention, the language, and the daily ability of the complex tools can be slightly damaged; There is no evidence of dementia and mild condition, and there is no evidence of serious social or professional ability; there is one of the A-type biomarkers and/ or neuronal damage markers in the imaging and cerebrospinal fluid detection; All subjects and their guardians informed consent to the study and signed the informed consent form; 3. The dementia of frontal lobe and leaf is enrolled in the criteria for diagnosis of Jee Bang in 2015: the symptoms of progressive and progressive mental behavior, the execution of dysfunction and the language damage are the main symptoms; These include the following three types: behavior variant, leaf dementia, primary progressive aphasia (including progressive non-fluent aphasia and semantic dementia); and imaging cues: the frontal and/ or leaf atrophy; All subjects and their guardians informed consent to the study and signed the informed consent form; 4. Lewy body dementia was enrolled in the following diagnostic criteria such as McKeith,2017: dementia, progressive cognitive decline, and normal social and working ability; The four clinical characteristics of the present invention are as follows: Volatility cognitive disorders, repeated visual hallucinations, fast-moving sleep behavior disorders, core symptoms of one or more spontaneous parkinsonism (Parkinson's symptoms and dementia occurring within a year), high sensitivity to antipsychotic drugs, and the like; All subjects and their guardians informed consent to the study and signed the informed consent form; Parkinson's disease/ dementia was selected in accordance with the 2015 MDS and the 2007 MDS diagnostic criteria: slow movement of the patient, combined stationary tremor, and/ or muscle rigidity; A clear and significant effective response to the treatment of dopamine-capable drugs; the presence of levodopa-induced dyskinesia; a single limb-stationary tremor (prior or this test) recorded in a clinical physical examination; The at least one additional test result positive for the
Exclusion criteria
Exclusion criteria: Alzheimer's disease: 1. With HIV dementia, Huntington dementia, vascular dementia or other rare dementia overlapping with AD; 2. AD patients with negative A ß or neuron injury related biomarkers; 3. subjects who could not cooperate with the relevant examination. Mild cognitive impairment: 1. with history of cerebral vascular stroke, and there were clear symptoms or signs of neurological deficit at the time of onset, and the corresponding responsible lesions were left behind by neuroimaging; 2. with severe white matter disease, Fazekas score >=3; 3. consciousness disorder caused by any cause; 4. patients with severe aphasia or limb disability who could not complete neuropsychological examination; 5. patients with related depression (Hamilton depression scale score > 8) or mental illness; 6. patients with history of alcoholism, or history of drug addiction, or brain injury, seizures, Encephalitis, normal intracranial pressure hydrocephalus and other neurological diseases that can cause cognitive impairment; 7. suffering from systemic diseases that may lead to mild cognitive impairment (such as liver and kidney insufficiency, endocrine diseases, vitamin deficiency, etc.); 8. subjects who could not cooperate with the relevant examination. Frontotemporal dementia: 1. symptoms more likely to be caused by other non-degenerative diseases of the nervous system or medical diseases; 2. abnormal behavior was more in line with the diagnosis of psychiatry; 3. biomarkers strongly suggested Alzheimer's disease or other neurodegenerative diseases; 4. subjects who could not cooperate with the relevant examinations; Louis body dementia: 1. focal nervous system signs or brain imaging evidence for cerebrovascular diseases; 2. other somatic diseases or brain diseases that could lead to similar clinical symptoms; 3. Parkinson's syndrome only appeared when dementia was serious; 4. subjects who could not cooperate with the relevant examination. Parkinson's disease: 1. clear cerebellar abnormalities, such as cerebellar gait, limb ataxia, or cerebellar eye movement abnormalities; 2. downward supranuclear gaze paralysis, or selective downward vertical scan deceleration; 3. within 5 years of onset, it was diagnosed as likely behavioral variant frontotemporal lobe dementia or primary progressive aphasia; 4. the onset of Parkinson's syndrome was still limited to lower extremity Parkinson's syndrome for more than 3 years; 5. dopamine receptor blocker or dopamine depletion agent was used in the treatment of Parkinson's syndrome, and the dose and time process was consistent with that of drug-induced Parkinson's syndrome; 6. although the condition was at least moderate severity, there was no observable therapeutic response to high dose levodopa treatment; 7. clear cortical sensory loss, clear motor aphasia or progressive aphasia of limb concept; 8. normal neuroimaging examination of presynaptic dopamine system function; 9. clearly recorded Parkinson's syndrome or other diseases suspected to be related to the symptoms of the patient; 10. subjects who could not cooperate with the relevant examination. Vascular dementia: 1. Cognitive impairment or mental and behavioral abnormalities within 3 months caused by drug / alcohol dependence; 2. subjects who could not cooperate with the relevant tests. Normal cognitive controls: 1. middle-aged and elderly people with other systemic severe diseases; 2. participants with dementia caused by r
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Phenotype and function of CD4 T cells;Gene expression of peripheral blood CD4+ T cells;BACE1 protein level in peripheral plasma;Aß1–42 in peripheral blood;Aß1–40 in peripheral;Cerebrospinal fluid tau content;Plasma BACE1 activity;Multimodal MRI variation characteristics;Characteristics of molecular imaging changes in 18F-FDG-PET and 18F-AV45-PET;Retinal changes;Retinal A beta deposition;Detection of peripheral blood related genes;Aß40/A beta 42 of cerebrospinal fluid;p-tau of cerebrospinal fluid;Relevant results of cognitive assessment;Cerebrospinal fluid exosome;cerebrospinal fluid NFL;cerebrospinal fluid non-target Metabonomics;Serum non-target Metabonomics;Other tissue Proteomics; | — |
Secondary
| Measure | Time frame |
|---|---|
| Serum ferritin;Iron index in cerebrospinal fluid; | — |
Countries
China
Contacts
Public ContactTang Qiqiang
First affiliated Hospital of China University of Science and Technology, Anhui Provincial Hospital
Outcome results
None listed